Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus (LASER) An External Comparator Arm Study for the TULIP Trials Using the University of Toronto Lupus Clinic Cohort

NCT06485674 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06485674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06485674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus (LASER) An External Comparator Arm Study for the TULIP Trials Using the University of Toronto Lupus Clinic Cohort
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 9, 2024
Completion date
June 24, 2025
Enrollment
561 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long-term organ damage in adult patients with active systemic lupus erythematosus